MetaCap

Aytu BioPharma (AYTU) vs Edesa Biotech (EDSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Edesa Biotech (EDSA) over the past year, gaining 32.3% versus a gain of 17.6%. Over five years, AYTU leads with a -93.2% price change compared with -95.6% for EDSA. Aytu BioPharma is the larger company by market cap ($28.9 million vs $27.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%EDSA+17.65%
+1027%+461%-104%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%EDSA-95.72%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus EDSA key metrics
MetricAYTUEDSA
Share price$2.66$2.00
Market cap$28.91M$27.02M
1-day change0.00%-8.05%
YTD return+2.31%+40.85%
1-year return+32.34%+17.65%
5-year return-93.21%-95.63%
Forward P/E17.16—
EPS (TTM)$-1.78$-1.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M—
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-7.19M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$20.32
52-week low$1.75$0.72
Distance from 52-week high-13.36%-90.16%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+716.50%
Average volume141.18K1.45M
Shares outstanding10.87M13.51M
Employees7517
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed EDSA by 14.7 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

AYTU vs EDSA FAQ

Which is bigger, Aytu BioPharma or Edesa Biotech?

Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $27.02M for Edesa Biotech (EDSA).

Which stock has performed better over the past year, AYTU or EDSA?

AYTU returned +32.34% over the past 12 months, compared with +17.65% for EDSA (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and Edesa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons